Literature DB >> 23626003

Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage.

Cosimo Giannini1, Ariel E Feldstein, Nicola Santoro, Grace Kim, Romy Kursawe, Bridget Pierpont, Sonia Caprio.   

Abstract

OBJECTIVE: Fibroblast growth factor (FGF)-21 is highly expressed in the liver and regulates glucose and lipid metabolism in rodents. The effects of obesity and fatty liver on circulating FGF-21 levels have been described mainly in adults. Herein, we measured plasma FGF-21 levels in lean and obese adolescents with low and high hepatic fat content (HFF% <5.5% and HFF% ≥ 5.5%, respectively) and explored their relationship with hepatic fat content, measures of hepatic apoptosis, and insulin sensitivity.
METHODS: A total of 217 lean and obese adolescents with both low and high HFF% (lean = 31; obese low HFF% = 107; and obese high HFF% = 79) underwent an oral glucose tolerance test, a fast gradient magnetic resonance imaging to measure the %HFF and abdominal fat distribution. Cytokeratin 18 levels were measured as a biomarker of liver apoptosis. A subset of adolescents underwent a 2-step hyperinsulinemic-euglycemic clamp, and a liver biopsy (N = 14), to assess insulin sensitivity and steatohepatitis, respectively.
RESULTS: Compared to controls, FGF-21 levels were higher in obese youth, especially in those with high HFF (P < .001). FGF-21 significantly correlated with adiposity indexes (P < .001), visceral fat (r² = 0.240, P < .001), hepatic fat content (r² = 0.278, P < .001), cytokeratin 18 (r² = 0.217, P < .001), and alanine aminotransferase (r² = .164, P < .001). In subjects with steatoheaptitis, FGF-21 levels significantly correlated with the nonalcoholic fatty liver disease activity score (r² = 0.27, P = .04). Stepwise regression analysis indicated that these relationships are independent of body mass index, visceral fat, and insulin sensitivity. An inverse correlation was documented with insulin, hepatic resistance indexes, and adipose resistance indexes, which disappeared after adjusting for hepatic fat content.
CONCLUSIONS: Plasma FGF-21 levels are increased in obese adolescents, particularly in those with fatty liver. FGF-21 concentrations significantly and independently correlate with hepatic fat content and markers of hepatic apoptosis in obese youths.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23626003      PMCID: PMC3701279          DOI: 10.1210/jc.2013-1250

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  35 in total

1.  The normal glucose tolerance continuum in obese youth: evidence for impairment in beta-cell function independent of insulin resistance.

Authors:  Catherine W Yeckel; Sara E Taksali; James Dziura; Ram Weiss; Tania S Burgert; Robert S Sherwin; William V Tamborlane; Sonia Caprio
Journal:  J Clin Endocrinol Metab       Date:  2004-11-02       Impact factor: 5.958

Review 2.  Fibroblast growth factors as regulators of stem cell self-renewal and aging.

Authors:  Joyce S G Yeoh; Gerald de Haan
Journal:  Mech Ageing Dev       Date:  2006-11-21       Impact factor: 5.432

3.  Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat.

Authors:  Tania S Burgert; Sara E Taksali; James Dziura; T Robin Goodman; Catherine W Yeckel; Xenophon Papademetris; R Todd Constable; Ram Weiss; William V Tamborlane; Mary Savoye; Aisha A Seyal; Sonia Caprio
Journal:  J Clin Endocrinol Metab       Date:  2006-08-15       Impact factor: 5.958

4.  Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis.

Authors:  Thomas Reinehr; Joachim Woelfle; Rainer Wunsch; Christian L Roth
Journal:  J Clin Endocrinol Metab       Date:  2012-03-21       Impact factor: 5.958

5.  The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.

Authors:  Alexei Kharitonenkov; Victor J Wroblewski; Anja Koester; Yun-Fei Chen; Cathleen K Clutinger; Xenia T Tigno; Barbara C Hansen; Armen B Shanafelt; Garret J Etgen
Journal:  Endocrinology       Date:  2006-10-26       Impact factor: 4.736

6.  FGF-21 as a novel metabolic regulator.

Authors:  Alexei Kharitonenkov; Tatiyana L Shiyanova; Anja Koester; Amy M Ford; Radmila Micanovic; Elizabeth J Galbreath; George E Sandusky; Lisa J Hammond; Julie S Moyers; Rebecca A Owens; Jesper Gromada; Joseph T Brozinick; Eric D Hawkins; Victor J Wroblewski; De-Shan Li; Farrokh Mehrbod; S Richard Jaskunas; Armen B Shanafelt
Journal:  J Clin Invest       Date:  2005-05-02       Impact factor: 14.808

7.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

8.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

9.  Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning.

Authors:  Ram Weiss; Sylvie Dufour; Sara E Taksali; William V Tamborlane; Kitt F Petersen; Riccardo C Bonadonna; Linda Boselli; Gina Barbetta; Karin Allen; Francis Rife; Mary Savoye; James Dziura; Robert Sherwin; Gerald I Shulman; Sonia Caprio
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

10.  BetaKlotho is required for metabolic activity of fibroblast growth factor 21.

Authors:  Yasushi Ogawa; Hiroshi Kurosu; Masaya Yamamoto; Animesh Nandi; Kevin P Rosenblatt; Regina Goetz; Anna V Eliseenkova; Moosa Mohammadi; Makoto Kuro-o
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-23       Impact factor: 11.205

View more
  41 in total

1.  Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.

Authors:  Laurie R Braun; Meghan N Feldpausch; Natalia Czerwonka; Martin Torriani; Steven K Grinspoon; Takara L Stanley
Journal:  Growth Horm IGF Res       Date:  2017-10-07       Impact factor: 2.372

2.  Fibroblast growth factor 21 is regulated by the IRE1α-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis.

Authors:  Shan Jiang; Cheng Yan; Qi-chen Fang; Meng-le Shao; Yong-liang Zhang; Yang Liu; Yi-ping Deng; Bo Shan; Jing-qi Liu; Hua-ting Li; Liu Yang; Jian Zhou; Zhi Dai; Yong Liu; Wei-ping Jia
Journal:  J Biol Chem       Date:  2014-08-28       Impact factor: 5.157

3.  Nonalcoholic fatty liver disease and the heart in children and adolescents.

Authors:  Lucia Pacifico; Claudio Chiesa; Caterina Anania; Antonio De Merulis; John Frederick Osborn; Sara Romaggioli; Eugenio Gaudio
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

4.  Fibroblast growth factor-21, body composition, and insulin resistance in pre-pubertal and early pubertal males and females.

Authors:  Lynae J Hanks; Krista Casazza; Ambika P Ashraf; Stephenie Wallace; Orlando M Gutiérrez
Journal:  Clin Endocrinol (Oxf)       Date:  2014-08-08       Impact factor: 3.478

Review 5.  Is there a paradox in obesity?

Authors:  Akankasha Goyal; Kameswara Rao Nimmakayala; Joel Zonszein
Journal:  Cardiol Rev       Date:  2014 Jul-Aug       Impact factor: 2.644

6.  Quantification of 1H NMR Spectra from Human Plasma.

Authors:  Robin A de Graaf; Hetty Prinsen; Cosimo Giannini; Sonia Caprio; Raimund I Herzog
Journal:  Metabolomics       Date:  2015-07-05       Impact factor: 4.290

Review 7.  Thyroid hormone regulation of metabolism.

Authors:  Rashmi Mullur; Yan-Yun Liu; Gregory A Brent
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

8.  Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.

Authors:  Diana Barb; Fernando Bril; Srilaxmi Kalavalapalli; Kenneth Cusi
Journal:  J Clin Endocrinol Metab       Date:  2019-08-01       Impact factor: 5.958

9.  Circulating levels of fibroblast growth factor 21 in early-stage diabetic kidney disease.

Authors:  A Esteghamati; A Khandan; A Momeni; A Behdadnia; A Ghajar; M S Nikdad; S Noshad; M Nakhjavani; M Afarideh
Journal:  Ir J Med Sci       Date:  2017-02-08       Impact factor: 1.568

Review 10.  FGF21 in obesity and cancer: New insights.

Authors:  Weiqin Lu; Xiaokun Li; Yongde Luo
Journal:  Cancer Lett       Date:  2020-11-29       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.